VRCA Begins COVE-3 Trial
Verrica Pharmaceuticals announces the first US patient dosed in the COVE-3 trial for YCANTH to treat common warts
VRCA - Verrica Pharmaceuticals Announces First U.S.
Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts